Angiotensin-converting enzyme inhibitors (ACEI) are widely used in the management of hypertension, heart failure, myocardial infarction, renal failure, and kidney diseases. ACEI produced a 10% reduction in all-cause mortality and a 12% reduction in cardiovascular mortality in hypertensive patients [1]. They represent the first-line therapy in cardiovascular protection in the group of renin angiotensin aldosterone system (RAAS). Generally, they are well-tolerated by most patients. However, cough is a well-known side effect with this drug class, and the cough can be severe enough to require medication discontinuation.
